(Q40952504)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8573312%20AND%20SRC:MED&resulttype=core&format=json

14 October 2019

review article

1 reference

title

Manipulation of costimulatory signals to enhance antitumor T-cell responses (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8573312%20AND%20SRC:MED&resulttype=core&format=json

14 October 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8573312%20AND%20SRC:MED&resulttype=core&format=json

14 October 2019

author name string

A A Hurwitz

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8573312%20AND%20SRC:MED&resulttype=core&format=json

14 October 2019

D R Leach

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8573312%20AND%20SRC:MED&resulttype=core&format=json

14 October 2019

publication date

1 October 1995

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8573312%20AND%20SRC:MED&resulttype=core&format=json

Current Opinion in Immunology

14 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8573312%20AND%20SRC:MED&resulttype=core&format=json

14 October 2019

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8573312%20AND%20SRC:MED&resulttype=core&format=json

14 October 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8573312%20AND%20SRC:MED&resulttype=core&format=json

14 October 2019

page(s)

682-686

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8573312%20AND%20SRC:MED&resulttype=core&format=json

CTLA-4 can function as a negative regulator of T cell activation

14 October 2019

cites work

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1016/1074-7613(94)90071-X

CD28-B7 interactions in T-cell activation.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0952-7915(95)80077-8

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0952-7915(95)80077-8

Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0952-7915(95)80077-8

CD28 ligands CD80 (B7-1) and CD86 (B7-2) induce long-term autocrine growth of CD4+ T cells and induce similar patterns of cytokine secretion in vitro

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0952-7915(95)80077-8

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0952-7915(95)80077-8

Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0952-7915(95)80077-8

B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0952-7915(95)80077-8

Proliferating dendritic cell progenitors in human blood

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0952-7915(95)80077-8

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0952-7915(95)80077-8

Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy?

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0952-7915(95)80077-8

CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0952-7915(95)80077-8

In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0952-7915(95)80077-8

Analysis of lymphocyte costimulation in vivo using transgenic and 'knockout' mice

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0952-7915(95)80077-8

Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0952-7915(95)80077-8

Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0952-7915(95)80077-8

Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0952-7915(95)80077-8

Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0952-7915(95)80077-8

B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0952-7915(95)80077-8

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0952-7915(95)80077-8

Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0952-7915(95)80077-8

Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0952-7915(95)80077-8

Tumor immunotherapy: the tumor cell as an antigen-presenting cell

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0952-7915(95)80077-8

The B7 and CD28 receptor families

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/0952-7915(95)80077-8

Identifiers

DOI

10.1016/0952-7915(95)80077-8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8573312%20AND%20SRC:MED&resulttype=core&format=json

14 October 2019

1 reference